Patents by Inventor Yves-Marie Coic

Yves-Marie Coic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10138280
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: November 27, 2018
    Assignee: Institut Pasteur
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Patent number: 9907860
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 6, 2018
    Assignees: INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS-SUD, UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Francoise Baleux, Hugues Lortat-Jacob, David Bonnaffe, Yves-Marie Coic
  • Publication number: 20170326246
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Application
    Filed: October 23, 2015
    Publication date: November 16, 2017
    Inventors: Francoise BALEUX, Hugues LORTAT-JACOB, David BONNAFFE, Yves-Marie COÏC
  • Publication number: 20160318981
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Application
    Filed: June 9, 2016
    Publication date: November 3, 2016
    Applicant: INSTITUT PASTEUR
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Patent number: 9382299
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 5, 2016
    Assignee: Institut Pasteur
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Publication number: 20140336119
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 13, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Publication number: 20100240040
    Abstract: The invention relates to methods for screening for selective modulator of NF-?B pathway activation. The invention concerns methods for primary screening molecules that potentially modulate (activate or inhibit) the NF-?B pathway activation by identifying and selecting molecules modulate the interaction of NEMO with other proteins. The invention also concerns methods for secondary screening for modulator (activator or inhibitor) of the NF-?B pathway activation.
    Type: Application
    Filed: June 20, 2008
    Publication date: September 23, 2010
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scient.
    Inventors: Fabrice Agou, Jeanne Chiaravalli, Yves-Marie Coic, Francoise Baleux, Alain Israel, Michel Veron
  • Patent number: 7700553
    Abstract: The present invention relates to polypeptides that inhibit the NF-&kgr;B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: April 20, 2010
    Assignees: Institut Pasteur, INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National De La Recherche Scientifique
    Inventors: Fabrice Agou, Gilles Courtois, Alain Israel, Michel Veron, Francois Traincard, Shoji Yamaoka, Yves-Marie Coic, Francoise Baleux
  • Publication number: 20080242601
    Abstract: The present invention relates to polypeptides that inhibit the NF-&kgr; B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
    Type: Application
    Filed: September 24, 2004
    Publication date: October 2, 2008
    Applicants: Institute Pasteur, Inserm (Inst.Nat.de la Sante et de la Rech.Med., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Fabrice Agou, Gilles Courtois, Alain Israel, Michel Veron, Francois Traincard, Shoji Yamaoka, Yves-Marie Coic, Francoise Baleux